Emma, Indiana Emma, Indiana Living with type 1 diabetes for 24 years, Emma began GLP-1 therapy in 2024
A collaborative discussion between patient and provider can determine the most appropriate course of action, which may include further diagnostic evaluation, treatment of underlying contributing factors, symptomatic management of RLS, or consideration of alternative diabetes or weight management therapies if symptoms are severe and refractory to other interventions
In some embodiments, the formulation or composition has a viscosity of at least about 10 cP, about 20 cP, about 30 cP, about 40 cP, about 50 cP, about 60 cP, about 70 cP, about 80 cP, about 90 cP, about 100 cP, about 200 cP, about 300 cP, about 400 cP, about 500 cP, about 600 cP, about 700 cP, about 800 cP, about 900 cP, about 1,000 cP, about 2,000 cP, about 3,000 cP, about 4,000 cP, about 5,000 cP, about 6,000 cP, about 7,000 cP, about 8,000 cP, about 9,000 cP, about 10,000 cP, about 15,000 cP, or about 20,000 cP
Expressed primarily in the central nervous system, particularly in hypothalamic and brainstem regions involved in appetite regulation and central signaling
Several additional antioxidants exhibit protective effects, mainly by reducing ROS and stabilizing mitochondria